The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC).
 
Pedro Barata
Honoraria - UroToday
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Ipson; Merck; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Bayer (Inst); Caris Life Sciences (Inst); Merck; Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Exelixis; Merck (Inst); Pfizer (Inst)
 
June Corrigan
No Relationships to Disclose
 
John Culnan
No Relationships to Disclose
 
Karlynn Dulberger
Patents, Royalties, Other Intellectual Property - BioNTech (I)
 
Jennifer La
Research Funding - Merck (Inst)
 
Elliot Akama-Garren
Consulting or Advisory Role - Roche
 
Clark DuMontier
Stock and Other Ownership Interests - Lilly
 
Jason Hansen
No Relationships to Disclose
 
Rhonda Bitting
No Relationships to Disclose
 
Heather Cheng
Consulting or Advisory Role - Janssen Oncology
Research Funding - Clovis Oncology (Inst); Janssen (Inst); Phosplatin Therapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Matthew Cooperberg
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Dendreon; Janssen; LynxDx; Merck; Pfizer; Tempus; Veracyte; Verana Health
 
Tanya Dorff
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Hookipa Biotech (Inst); Janssen Oncology (Inst); Promontory Therapeutics (Inst)
 
Susan Halabi
Employment - ASCO
Consulting or Advisory Role - Aveo; Bristol-Myers Squibb; CG Oncology; J&J; Sanofi
Research Funding - Astellas Pharma (Inst)
 
Stacy Loeb
Stock and Other Ownership Interests - Gilead Sciences (I)
Consulting or Advisory Role - Astellas Pharma; Doceree
Research Funding - Astellas Pharma
 
David Nanus
Honoraria - Janssen Oncology; Telix Pharmaceuticals
Consulting or Advisory Role - Telix Pharmaceuticals
Speakers' Bureau - Janssen Oncology
Research Funding - Exelixis; Zenith Epigenetics
Other Relationship - Genentech/Roche
 
Chong-xian Pan
Stock and Other Ownership Interests - Accelerated Medical Diagnostics; LP Therapeutics; Pandomedx
 
Martin Schoen
Consulting or Advisory Role - ConcertAI
Research Funding - Astellas Pharma (Inst)
 
Nathanael Fillmore
Research Funding - Merck (Inst)
 
Channing Paller
Consulting or Advisory Role - AstraZeneca; Bayer; Dendreon; Exelixis; Janssen Oncology; Omnitura; Pfizer
Research Funding - Lilly (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer
 
Matthew Rettig
Consulting or Advisory Role - INMune Bio
Speakers' Bureau - Bayer; Johnson & Johnson
Research Funding - Arvinas (Inst); Fortis (Inst); Novartis (Inst); Progenics
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet.
Travel, Accommodations, Expenses - Johnson & Johnson
 
PROFOUND-VET Investigators Group
No Relationships to Disclose